Your browser is no longer supported. Please, upgrade your browser.
Settings
ALBO [NASD]
Albireo Pharma, Inc.
Index- P/E- EPS (ttm)-2.58 Insider Own0.60% Shs Outstand19.26M Perf Week-4.80%
Market Cap462.52M Forward P/E- EPS next Y-6.52 Insider Trans-13.51% Shs Float16.83M Perf Month-15.88%
Income-47.90M PEG- EPS next Q-0.35 Inst Own84.50% Short Float6.64% Perf Quarter-20.25%
Sales10.80M P/S42.83 EPS this Y-33.50% Inst Trans-1.86% Short Ratio7.49 Perf Half Y-28.91%
Book/sh9.44 P/B2.52 EPS next Y-1.00% ROA-18.20% Target Price76.00 Perf Year-35.64%
Cash/sh13.50 P/C1.76 EPS next 5Y- ROE-30.70% 52W Range23.51 - 43.41 Perf YTD-36.60%
Dividend- P/FCF- EPS past 5Y-0.90% ROI- 52W High-46.46% Beta1.38
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin96.00% 52W Low-1.16% ATR1.28
Employees90 Current Ratio8.20 Sales Q/Q76.20% Oper. Margin- RSI (14)27.51 Volatility5.77% 4.80%
OptionableYes Debt/Eq0.00 EPS Q/Q248.40% Profit Margin- Rel Volume0.77 Prev Close23.78
ShortableYes LT Debt/Eq0.05 EarningsNov 04 BMO Payout- Avg Volume149.08K Price23.24
Recom1.50 SMA20-16.06% SMA50-20.60% SMA200-26.92% Volume62,244 Change-2.27%
Dec-18-20Reiterated H.C. Wainwright Buy $67 → $75
Aug-19-20Reiterated H.C. Wainwright Buy $64 → $50
Jul-31-20Initiated Piper Sandler Overweight $45
Jun-25-20Initiated Robert W. Baird Outperform $52
Feb-28-19Initiated H.C. Wainwright Buy $62
Apr-20-18Initiated Jefferies Buy $50
Nov-15-17Initiated ROTH Capital Buy $92
Jul-18-17Initiated Needham Buy $35
Jun-30-17Initiated Wedbush Outperform $58
Feb-16-17Initiated Ladenburg Thalmann Buy $40
Nov-18-21 08:08PM  
Nov-12-21 08:00AM  
Nov-10-21 08:30AM  
Nov-04-21 10:02PM  
09:45AM  
08:30AM  
Oct-28-21 03:05PM  
08:30AM  
Oct-15-21 08:30AM  
Oct-12-21 12:00PM  
08:30AM  
Oct-06-21 06:32AM  
Oct-05-21 08:30AM  
Sep-15-21 08:30AM  
Sep-08-21 04:30PM  
08:30AM  
Sep-07-21 08:30AM  
Sep-02-21 08:30AM  
Aug-18-21 01:30AM  
Aug-07-21 01:00PM  
Aug-05-21 09:35AM  
08:30AM  
Aug-03-21 08:30AM  
Jul-29-21 08:30AM  
Jul-21-21 10:51AM  
06:10AM  
Jul-20-21 05:21PM  
04:00PM  
08:59AM  
Jul-19-21 09:35AM  
08:01AM  
Jul-08-21 08:30AM  
Jun-24-21 08:00AM  
Jun-21-21 11:05AM  
06:00AM  
Jun-10-21 08:30AM  
Jun-03-21 04:30PM  
May-26-21 09:05AM  
08:30AM  
May-21-21 08:35AM  
May-19-21 09:14AM  
08:30AM  
May-07-21 05:31PM  
04:01PM  
May-06-21 09:45AM  
08:30AM  
Apr-29-21 08:30AM  
Apr-13-21 08:30AM  
Apr-06-21 08:30AM  
Mar-25-21 08:30AM  
Feb-27-21 01:09AM  
Feb-26-21 08:30AM  
12:31AM  
Feb-25-21 08:00AM  
Feb-23-21 08:30AM  
Feb-18-21 08:30AM  
Feb-17-21 04:30PM  
Feb-11-21 08:30AM  
Feb-05-21 12:03AM  
Jan-25-21 08:00AM  
Jan-22-21 08:30AM  
Jan-14-21 04:30PM  
Jan-07-21 08:30AM  
Jan-06-21 04:30PM  
Jan-05-21 08:30AM  
Dec-29-20 09:25AM  
Dec-24-20 09:54AM  
Dec-19-20 06:11PM  
Dec-17-20 08:00AM  
Dec-11-20 04:30PM  
Dec-08-20 04:30PM  
Nov-30-20 09:02AM  
Nov-20-20 10:45AM  
Nov-13-20 08:05AM  
Nov-12-20 08:00AM  
Nov-07-20 07:21AM  
Nov-05-20 07:30AM  
Nov-02-20 08:00AM  
Oct-23-20 09:20AM  
Oct-20-20 09:03AM  
Oct-05-20 08:30AM  
Oct-02-20 04:30PM  
Sep-19-20 07:00AM  
Sep-15-20 11:28AM  
Sep-09-20 09:16PM  
10:19AM  
10:08AM  
07:23AM  
Sep-08-20 04:01PM  
12:34PM  
06:30AM  
Sep-07-20 04:36PM  
Sep-03-20 08:47AM  
Aug-27-20 08:04AM  
Aug-21-20 09:00AM  
Aug-19-20 10:17AM  
Aug-18-20 04:40PM  
Aug-06-20 07:30AM  
Jul-30-20 04:01PM  
08:00AM  
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duncan JasonChief Legal Officer and GCOct 25Sale29.212176,3397,355Oct 25 06:30 PM
Duncan JasonChief Legal Officer and GCOct 22Sale28.85952,7417,572Oct 25 06:30 PM
Horn Patrick TaylorChief Medical OfficerOct 22Sale28.83952,73912,355Oct 25 06:41 PM
Harford Simon N.R.CFO and TreasurerOct 11Sale30.23932,81212,614Oct 12 04:01 PM
Stephenson PamelaChief Commercial OfficerSep 27Sale32.0545114,45626,063Sep 28 04:32 PM
Cooper Ronald Harold WilfredPresident and CEOSep 17Option Exercise19.1911,973229,76268,433Sep 20 04:03 PM
Duncan JasonChief Legal Officer and GCJul 23Sale31.432237,0097,667Jul 26 04:05 PM
Horn Patrick TaylorChief Medical OfficerJul 22Sale34.13903,07212,450Jul 26 04:06 PM
Duncan JasonChief Legal Officer and GCJul 22Sale34.13903,0727,890Jul 26 04:05 PM
Harford Simon N.R.CFO and TreasurerJul 13Sale35.02983,43212,707Jul 15 04:48 PM
Duncan JasonChief Legal Officer and GCJun 25Option Exercise24.676,300155,42114,280Jun 28 04:01 PM
Stephenson PamelaChief Commercial OfficerJun 25Sale36.0147116,96126,514Jun 28 04:02 PM
Duncan JasonChief Legal Officer and GCJun 25Sale36.226,300228,1867,980Jun 28 04:01 PM
Duncan JasonChief Legal Officer and GCJun 24Option Exercise24.0910,000240,94417,980Jun 28 04:01 PM
Duncan JasonChief Legal Officer and GCJun 24Sale36.3810,000363,8007,980Jun 28 04:01 PM
Duncan JasonChief Legal Officer and GCApr 23Sale32.322227,1757,849Apr 26 06:13 PM
Duncan JasonChief Legal Officer and GCApr 22Sale31.75902,8588,071Apr 26 06:13 PM
Horn Patrick TaylorChief Medical OfficerApr 22Sale31.75902,85811,893Apr 26 06:10 PM
Harford Simon N.R.CFO and TreasurerApr 12Sale32.12922,95512,196Apr 14 04:31 PM
Duncan JasonChief Legal Officer and GCApr 01Option Exercise24.043007,2128,461Apr 02 08:55 PM
Duncan JasonChief Legal Officer and GCApr 01Sale36.1630010,8478,161Apr 02 08:55 PM
Duncan JasonChief Legal Officer and GCMar 31Sale35.041,42649,9698,161Apr 02 08:55 PM
Stephenson PamelaChief Commercial OfficerMar 29Sale34.0242214,35526,985Mar 31 07:21 PM
Mattsson JanChief Scientific OfficerMar 03Sale36.2040014,48137,574Mar 03 06:45 PM
Mattsson JanChief Scientific OfficerMar 02Sale36.2815,770572,20737,974Mar 03 06:45 PM
Mattsson JanChief Scientific OfficerMar 01Option Exercise1.0039,33039,33069,044Mar 03 06:45 PM
Mattsson JanChief Scientific OfficerMar 01Sale37.4515,300572,99653,744Mar 03 06:45 PM
Duncan JasonChief Legal Officer and GCJan 22Sale34.621103,8089,332Jan 25 05:44 PM
Horn Patrick TaylorChief Medical OfficerJan 22Sale34.621103,8089,825Jan 25 05:37 PM
Harford Simon N.R.CFO and TreasurerJan 11Sale37.331104,1074,614Jan 13 04:15 PM
Stephenson PamelaChief Commercial OfficerDec 28Sale39.0746017,97421,907Dec 29 04:19 PM